| 陈 皎,杨玉琮,岳丽娟,魏少军,李雄海.卵巢癌患者血清HE4、CA125、CA72-4及炎性因子水平检测的临床价值评估[J].现代生物医学进展英文版,2019,19(4):700-703. |
| 卵巢癌患者血清HE4、CA125、CA72-4及炎性因子水平检测的临床价值评估 |
| Evaluation of the Clinical Value of serum HE4, CA125, CA72-4 and Inflammatory Factors Levels for the Patients with Ovarian Cancer |
| Received:May 28, 2018 Revised:June 23, 2018 |
| DOI：10.13241/j.cnki.pmb.2019.04.021 |
| 中文关键词: 肿瘤标记物 炎性因子 卵巢癌 |
| 英文关键词: Tumor marker Inflammatory factors Ovarian cancer |
| 基金项目:陕西省科技厅一般项目(2017SF-074) |
| Author Name | Affiliation | E-mail | | CHEN Jiao | Xi'an Jiaotong University, Xi'an, Shaanxi, 710049, China | cj32685@163.com | | YANG Yu-cong | Department of clinical laboratory, The first affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China | | | YUE Li-juan | Department of Oncology, Hanzhong Central Hospital, Hanzhong, Shaanxi, 723000, China | | | WEI Shao-jun | Clinical Laboratory, Hanzhong Central Hospital, Hanzhong, Shaanxi, 723000, China | | | LI Xiong-hai | Clinical Laboratory, Hanzhong Central Hospital, Hanzhong, Shaanxi, 723000, China | |
|
| Hits: 863 |
| Download times: 706 |
| 中文摘要: |
| 摘要 目的：探讨血清人附睾蛋白4(HE4)、糖类抗原125(CA125)、糖类抗原72-4(CA72-4)及炎性因子IL-6、IL-8、IL-17水平检测对卵巢癌患者的临床价值。方法：选取2015年2月至2017年2月我院收治的卵巢肿瘤患者81例，包括卵巢恶性肿瘤组39例及卵巢良性肿瘤组42例，另选42例健康人作正常对照组，比较各组及临床不同分期卵巢癌患者血清HE4、CA125、CA72-4、IL-6、IL-8、IL-17水平的差异。结果：卵巢恶性肿瘤组血清HE4、CA125、CA72-4、IL-6、IL-8及IL-17水平均显著高于对照组(P<0.05)，而卵巢良性肿瘤组与对照组以上指标比较差异并无统计学意义(P＞0.05)；随卵巢癌分期增加，患者血清HE4、CA125、CA72-4、IL-6、IL-8及IL-17水平呈上升趋势，以血清HE4、CA125及IL-17增加较为显著(P<0.05)，而Ⅰ期、Ⅱ期及Ⅲ期卵巢癌患者血清CA72-4、IL-6及IL-8在增加并不明显(P＞0.05)。结论：卵巢癌患者血清HE4、CA125、CA72-4、IL-6、IL-8及IL-17水平较高，且随临床分期增加呈上升趋势，以上指标可能有助于卵巢癌的诊断、治疗及病情评估。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical value of serum human epididymis 4 (HE4), carbohydrate antigen 125 (CA125), car- bohydrate antigen 72-4 (CA72-4), IL-6, IL-8 and IL-17 for the ovarian cancer patients. Methods: 81 cases of patients with ovarian tumors from February 2015 to February 2017 in our hospital were selected and divided into the ovarian cancer group(39 cases) and the benign ovarian tumor group(42 cases), 42 healthy people were selected as the normal control group, the serum levels of HE4, CA125, CA72-4, IL-6, IL-8 and IL-17 were compared between different groups and ovarian cancer patients at different stages. Results: The levels of serum HE4, CA125, CA72-4, IL-6, IL-8 and IL-17 of ovarian malignant tumor group were all significantly higher than those in the control group (P<0.05), there was no significant difference in the above indexes between benign ovarian tumor group and control group(P>0.05). The levels of serum HE4, CA125, CA72-4, IL-6, IL-8 and IL-17 were increased with the increase of ovarian cancer stage, the increase of serum HE4, CA125 and IL-17 were more significant (P<0.05), while CA72-4, IL-6 and IL-17 showed no significantincrease at stage I, II and III of ovarian cancer(P>0.05). Conclusion: The serum levels of HE4, CA125, CA72-4, IL-6, IL-8 and IL-17 were higher in patients with ovarian cancer and increased with the increase of clinical stages. The above indicators may be helpful to the diagnosis, treatment and evaluation of ovarian cancer. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
